Baidu
map

研究设计

订阅

MedSci主页 / 所有栏目 / 研究设计

Meta分析制胜法宝——诊断实验的价值与筛选

2022-06-09 田金徽 MedSci原创

循证医学临床研究设计
关注

兰州大学循证医学研究所

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897019, encodeId=eab7189e01994, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 27 19:22:46 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888437, encodeId=97b8188843ed8, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Sep 05 19:22:46 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584476, encodeId=116415844e624, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jun 11 00:22:46 CST 2022, time=2022-06-11, status=1, ipAttribution=)]
    2022-06-27 一闲

    #MET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1897019, encodeId=eab7189e01994, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 27 19:22:46 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888437, encodeId=97b8188843ed8, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Sep 05 19:22:46 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584476, encodeId=116415844e624, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jun 11 00:22:46 CST 2022, time=2022-06-11, status=1, ipAttribution=)]
    2022-09-05 guojianrong

    #Meta#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1897019, encodeId=eab7189e01994, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Jun 27 19:22:46 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888437, encodeId=97b8188843ed8, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Sep 05 19:22:46 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584476, encodeId=116415844e624, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sat Jun 11 00:22:46 CST 2022, time=2022-06-11, status=1, ipAttribution=)]
    2022-06-11 ms6747015003810650

    #筛选#

    0

相关资讯

第十届亚太地区循证医学研讨会召开，推动循证中医药学发展

以“循证医学的新时代”为主题的第十届亚太地区循证医学研讨会、第三届循证中医药学国际论坛暨首届世界人工智能健康管理论坛在天津举办。此次会议将循证医学、中医药学和人工智能三个领域跨界融合在同一学术平台，探讨了“EBM+TCM+AI”三位一体发展模式，将为慢病防控和健康管理贡献新的思路和智慧，在行业内具有重要意义。

Semin Arthritis Rheu：幼年特发性关节炎相关性葡萄膜炎抗炎治疗循证、跨学科指南的更新

如果局部应用低剂量糖皮质激素（≤2次/天）无效，应引入甲氨蝶呤；如果没有达到非活动性葡萄膜炎，则使用TNFα抗体（首选阿达木单抗）。

林国庆：奏响医学科技强大音

“医学与生命关系紧密，准确和安全性十分重要。所以，就算时代的节奏变化很快，我们也必须保证，务必在坚持循证医学的理念下，创新医疗服务模式，探索科技进展。”

Circulation：心血管病精准治疗概念框架：针对脂蛋白、炎症、代谢、血小板和凝血靶标，多种新药决择有依据

近期，Circulation杂志上的一篇文章提出了心血管病精准治疗概念框架。

从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗

基于循证医学证据的更新，中国抗癌协会肺癌专业委员会外科学组制定了《非小细胞肺癌术后辅助治疗中国胸外科专家共识（2018版）》。【肿瘤资讯】特邀专家组成员，苏州大学附属第一医院的马海涛教授，为大家讲述专家共识中对于EGFR-TKI术后辅助靶向治疗的推荐人群及其背后的临床证据。此外，对于临床上非常关注的寡转移的治疗，马教授也为大家做了深入介绍。

从被动接受治疗到主动参与维权，如何让患者获得更满意的医疗沟通？

癌症患者信息需求的最佳证据是什么？

Baidu
map
Baidu
map
Baidu
map